Popular weight loss drugs promise to slim waistlines and improve our general health, but they also come with some unpleasant ...

Semaglutide, a synthetic analog of glucagon-like peptide-1 (GLP-1), has garnered attention for its intriguing properties and potential implications in various r ...

Older adults taking GLP-1 receptor agonists, primarily semaglutide (Rybelsus, Ozempic, Wegovy), had a small uptick in their ...

The following is a summary of “Oral semaglutide for the treatment of obesity: a retrospective real-world study,” published in ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

By pairing semaglutide with one or two experimental antibodies designed to preserve muscle, participants lost less lean body ...

A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy, ...

Researchers have zeroed in on yet another possible ocular concern for diabetes patients who take popular GLP-1 therapies in a ...

A popular weight-loss drug may be changing how doctors treat obesity—but scientists are just starting to uncover exactly how ...

Given the evidence, the committee has recommended that the labels for Novo Nordisk’s Wegovy and Ozempic be updated to include ...

Semaglutide drugs now include rare vision risk warning as studies link long-term use to optic neuropathy, macular ...